Home / Priv. Doz. Dr. Sonia Vallet

Priv. Doz. Dr. Sonia Vallet

Arbeitsgruppe “Molekulare Onkologie/Hämatologie”

Vallet Sonia

Senior Scientist, Oberärztin am Universitätsklinikum Krems

Publikationen

  1. 2022

    • Zeitschriftenartikel

      • Dieckmann, K.-P., Pokrivcak, T., Geczi, L., Niehaus, D., Dralle-Filiz, I., Matthies, C., Dienes, T., Zschäbitz, S., Paffenholz, P., Gschliesser, T., Pichler, R., Mego, M., Bader, P., Zengerling, F., Heinzelbecker, J., Krausewitz, P., Krege, S., Aurilio, G., Aksoy, C., Hentrich, M., Seidel, C., Törzsök, P., Nestler, T., Majewski, M., Hiester, A., Buchler, T., Vallet, S., Studentova, H., Schönburg, S., Niedersüß-Beke, D., Ring, J., Trenti, E., Heidenreich, A., Wülfing, C., Isbarn, H., Pichlmeier, U. & Pichler, M., 2022. Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. Therapeutic advances in medical oncology, 14, S.17588359221086813.

      • Leisch, M., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Hartmann, B., Petzer, A., Schreder, M., Kiesl, D., Vallet, S., Egle, A., Melchardt, T., Piringer, G., Zebisch, A., Machherndl-Spandl, S., Wolf, D., Keil, F., Drost, M., Greil, R. & Pleyer, L., 2022. Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group. Cancers, 14(10), S.2459 [pii].

  2. 2021

    • Konferenzbeitrag

      • Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Poster: P-082: Delineating CDK9- regulated molecular events for the development of rationally derived multiple myeloma treatment strategies. In 18th International Myeloma Workshop. 08.-11.09.2021. Vienna, Austria, S. S83-S84.

      • Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Poster: Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy – Update. In OeGHO Frühjahrstagung. 8.-10.4.2021. Online, S. 23-41.

      • Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Zwickl-Traxler, E., Fan, F., Stoiber-Sakaguchi, D., Bakiri, L., Wagner, E., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Presentation: OAB-030: Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity. In 18th International Myeloma Workshop. 08.-11.09.2021. Vienna, Austria, S. S19-S20.

    • Zeitschriftenartikel

      • Aksoy, O., Lind, J., Sunder-Plassmann, V., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies. Blood, 138(Supplement 1), S.1598-1598.

      • Fan, F., Malvestiti, S., Vallet, S., Lind, J., Garcia-Manteiga, J.Manuel, Morelli, E., Jiang, Q., Seckinger, A., Hose, D., Goldschmidt, H., Stadlbauer, A., Sun, C., Mei, H., Pecherstorfer, M., Bakiri, L., Wagner, E.F., Tonon, G., Sattler, M., Hu, Y., Tassone, P., Jaeger, D. & Podar, K., 2021. JunB is a key regulator of multiple myeloma bone marrow angiogenesis. Leukemia.

      • Lind, J., Vallet, S., Kollmann, K., Aksoy, O., Sunder-Plassmann, V., Fan, F., Zwickl-Traxler, E., Stoiber-Sakaguchi, D., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2021. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs Inducing Synergistic Anti-Myeloma Activity. Blood, 138(Supplement 1), S.2644-2644.

      • Pozzi, S., Bari, A., Pecherstorfer, M. & Vallet, S., 2021. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. Cancers, 13(19), S.4978.

      • Singer, J., Le, N.-S., Mattes, D., Klamminger, V., Hackner, K., Kolinsky, N., Scherb, M., Errhalt, P., Kreye, G., Pecherstorfer, M., Vallet, S. & Podar, K., 2021. Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. Cancers, 13(17).

      • Zwickl, H., Zwickl-Traxler, E., Haushofer, A., Seier, J., Podar, K., Weber, M., Hackner, K., Jacobi, N., Pecherstorfer, M. & Vallet, S., 2021. Effect of cachexia on bone turnover in cancer patients: a case-control study. BMC Cancer, 21(1), S.744.

  3. 2020

    • Konferenzbeitrag

      • Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2020. Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy. In Abstractband für die Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020: Abstracts. 9.-11.10.2020. Online.

    • Andere wissenschaftliche Beiträge

      • Vallet, S., 2020. Kombinationstherapien in der Behandlung urogenitaler Tumoren. JATROS Hämatologie & Onkologie, (2).

  4. 2019

    • Konferenzbeitrag

      • Fan, F., Malvestiti, S., Shen, Y., Morelli, E., Mishima, Y., Seckinger, A., Hose, D., Bakiri, L., Vallet, S., Sattler, M., Roccaro, A.M., Goldschmidt, H., Percherstorfer, M., Sun, C., Hu, Y., Wagner, E.F., Tassone, P., Ghobrial, I.M., Jaeger, D. & Podar, K., 2019. Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.

      • Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Bakiri, L., Wagner, E.F., Sattler, M., Pecherstorfer, M. & Podar, K., 2019. Poster: Combined targeting of distinct c-Myc and JunB transcriptional programs for multiple myeloma therapy. In 17th International Myeloma Workshop. Boston.

      • Lind, J., Czernilofsky, F., Vallet, S., Fan, F., Sattler, M., Bakiri, L., Wagner, E.F., Percherstorfer, M. & Podar, K., 2019. Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.

      • Pleyer, L., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Petzer, A., Schmitt, C.A., Vallet, S., Mandac, I., Geissler, K., Sperr, W.R., Leisch, M., Egle, A., Melchardt, T., Fusinato, J., Piringer, G., Zebisch, A., Machherndl-Spandl, S., Wolf, D., Keil, F. & Greil, R., 2019. Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group. In American Society of Hematology, 61th Annual Meeting, scientific session. Orlando, FL.

    • Zeitschriftenartikel

      • Li, S., Vallet, S., Sacco, A., Roccaro, A., Lentzsch, S. & Podar, K., 2019. Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert opinion on investigational drugs, 28, S.445-462.

      • Lind, J., Czernilofsky, F., Vallet, S. & Podar, K., 2019. Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert opinion on emerging drugs, 24, S.133-152.

      • Vallet, S., Fan, F., Malvestiti, S., Pecherstorfer, M., Sattler, M., Schneeweiss, A., Schulze-Bergkamen, H., Opferman, J.T., Cardone, M.H., Jager, D. & Podar, K., 2019. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer. Breast cancer research and treatment, 173, S.585-596.

  5. 2018

    • Konferenzbeitrag

      • Malvestiti, S., Fan, F., Bashari, H.M., Morelli, E., Seckinger, A., Hose, D., Goldschmidt, H., Zoernig, I., Bakiri, L., Sattler, M., Vallet, S., Pecherstorfer, M., Wagner, E.F., Tassone, P., Jaeger, D. & Podar, K., 2018. Poster: Multiple myeloma pathogenesis: The role of JunB in bone marrow angiogenesis. In 23rd Congress of the European Hematology Association (EHA). Stockholm, Sweden.

    • Zeitschriftenartikel

      • Vallet, S., Filzmoser, J.M., Pecherstorfer, M. & Podar, K., 2018. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies. Pharmaceutics, 10, S.202.

      • Vallet, S., Hoyle, N.R., Kyle, R.A., Podar, K. & Pecherstorfer, M., 2018. A role for bone turnover markers beta-CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. Leukemia & Lymphoma, 59, S.2431-2438.

    • Andere wissenschaftliche Beiträge

      • Vallet, S., 2018. Checkpointblockade beim metastasierten Urothelkarzinom. JATROS Hämatologie & Onkologie, (2).

  6. 2017

    • Zeitschriftenartikel

      • Fan, F., Bashari, M.H., Morelli, E., Tonon, G., Malvestiti, S., Vallet, S., Jarahian, M., Seckinger, A., Hose, D., Bakiri, L., Sun, C., Hu, Y., Ball, C.R., Glimm, H., Sattler, M., Goldschmidt, H., Wagner, E.F., Tassone, P., Jaeger, D. & Podar, K., 2017. The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia, 31, S.1570-1581.

      • Rosenberger, F., Wiskemann, J., Vallet, S., Haag, G.M., Schembri, E., Jager, D. & Grüllich, C., 2017. Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy-a controlled feasibility trial. Support Care Cancer, 25, S.3655-3664.

      • Vallet, S., Pecherstorfer, M. & Podar, K., 2017. Adoptive cell therapy in multiple Myeloma. Expert Opinion on Biological Therapy, 17, S.1511-1522.

Forschungsprojekte

  • Biomarker-basierte therapeutische Prävention

    Biomarker-basierte therapeutische Prävention von Knochenmetastasen beim Mammakarzinom: Die pathophysiologische Rolle der endostalen Nische

    • Projektnummer: LSC18-010
    • Projektleitung: Sonia Vallet, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften / Molekulare Hämatologie / Onkologie, Sonia Vallet, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften / Klinische Abteilung für Innere Medizin 2 (UK Krems)
    • Projektpartner: IMC FH Krems / Department of Life Sciences
    • Projektlaufzeit: 36 Monate ab 01.12.2019

    Hintergrund

    Breast cancer (BC) is the most common malignancy in women. Most of the tumors are detected at early stages and treated with curative intent. However, up to one third of patients relapse, of which 70% develop bone metastases with survival rates dropping under 10% at 5 years. Efforts to find markers of bone metastases development have so far failed, mainly due to the poor understanding of early pathogenetic steps. Therefore, there remains a need for biomarkers that identify patients at high risk for bone metastases. In addition, despite the frequency of skeletal involvement and the associated morbidity and mortality, effective strategies to prevent bone metastases are lacking. Previous studies identified the endosteum as site of entry for bone metastatic BC cells, where OBs regulate tumor cell migration and survival. Specifically, our own data suggest a key role for pre-OBs in BC bone colonization. Here, I propose to unravel the pathophysiologic role of the endosteal niche, OB lineage cells in particular, during early phases of BM in BC by generating innovative in vitro models of OB differentiation.

Events

  1. 22 Jul

    PSYCHOLOGIE Meet & Greet

    22. Juli 2022, 16:00 - 18:00
    Karl Landsteiner Privatuniversität, Trakt Y
  2. 23 Jun

    Sektionstagung Kulturgerontologie – "Perspektiven auf das Alter(n)"

    23. Juni 2022, 09:00 - 25. Juni 2022, 17:00
    Karl Landsteiner Privatuniversität für Gesundheitswissenschaften, Trakt Y
  3. 20 Jun

    D.O.T. Abschlusskonferenz 2022

    20. Juni 2022, 14:00 - 16:00
    Online via MS Teams